HK1217490A1 - 黃斑變性治療中的新穎捕獲劑 - Google Patents

黃斑變性治療中的新穎捕獲劑 Download PDF

Info

Publication number
HK1217490A1
HK1217490A1 HK16105524.6A HK16105524A HK1217490A1 HK 1217490 A1 HK1217490 A1 HK 1217490A1 HK 16105524 A HK16105524 A HK 16105524A HK 1217490 A1 HK1217490 A1 HK 1217490A1
Authority
HK
Hong Kong
Prior art keywords
macular degeneration
treatment
traps
novel
novel traps
Prior art date
Application number
HK16105524.6A
Other languages
English (en)
Chinese (zh)
Inventor
John Clifford Chabala
Thomas A. Jordan
Ke-Qing LING
John G. Gleason
William A. Kinney
Original Assignee
Aldeyra Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aldeyra Therapeutics, Inc. filed Critical Aldeyra Therapeutics, Inc.
Publication of HK1217490A1 publication Critical patent/HK1217490A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK16105524.6A 2013-01-25 2014-01-21 黃斑變性治療中的新穎捕獲劑 HK1217490A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756778P 2013-01-25 2013-01-25
US61/756,778 2013-01-25
PCT/US2014/012356 WO2014116593A1 (en) 2013-01-25 2014-01-21 Novel traps in the treatment of macular degeneration

Publications (1)

Publication Number Publication Date
HK1217490A1 true HK1217490A1 (zh) 2017-01-13

Family

ID=51227964

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16105524.6A HK1217490A1 (zh) 2013-01-25 2014-01-21 黃斑變性治療中的新穎捕獲劑

Country Status (13)

Country Link
US (2) US10111862B2 (OSRAM)
EP (1) EP2948436A4 (OSRAM)
JP (1) JP6266023B2 (OSRAM)
KR (1) KR20150120380A (OSRAM)
CN (1) CN105228989A (OSRAM)
AU (1) AU2014209585A1 (OSRAM)
CA (1) CA2898869A1 (OSRAM)
HK (1) HK1217490A1 (OSRAM)
IL (1) IL239736A0 (OSRAM)
MX (1) MX2015009444A (OSRAM)
RU (1) RU2015126015A (OSRAM)
SG (1) SG11201505599YA (OSRAM)
WO (1) WO2014116593A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7973025B2 (en) 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
KR20150118106A (ko) 2012-12-20 2015-10-21 알데이라 테라퓨틱스, 아이엔씨. 페리-카르비놀
HK1217439A1 (zh) 2013-01-23 2017-01-13 Aldeyra Therapeutics, Inc. 与毒性醛相关的疾病和治疗
US20170298081A1 (en) * 2014-08-08 2017-10-19 Kasuma Partners Inc. Condensed heterocyclic compound
MX2018002155A (es) * 2015-08-21 2018-06-08 Aldeyra Therapeutics Inc Compuestos deuterados y usos de los mismos.
WO2017147617A1 (en) 2016-02-28 2017-08-31 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
CA3022665A1 (en) 2016-05-09 2017-11-16 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
ES2968462T3 (es) 2017-03-16 2024-05-09 Aldeyra Therapeutics Inc Sal polimórfica de 6-cloro-3-amino-2(2-hidroxiprolil) quinolina y usos de la misma
JP7311162B2 (ja) 2017-10-10 2023-07-19 アルデイラ セラピューティクス， インコーポレイテッド 炎症性障害の処置
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CN115869258A (zh) 2018-09-25 2023-03-31 奥尔德拉医疗公司 用于治疗干眼病的调配物
US11786518B2 (en) 2019-03-26 2023-10-17 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
WO2020223685A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CN114828857B (zh) * 2019-09-09 2024-11-12 联邦高等教育系统-匹兹堡大学 通过激活tfeb恢复视网膜色素上皮细胞的溶酶体功能的方法
CN113767090B (zh) * 2019-12-30 2024-05-28 中国医药研究开发中心有限公司 三环化合物及其制备方法和医药用途
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2086186A (en) 1933-10-10 1937-07-06 Us Rubber Co Treatment of rubber
GB1435721A (en) 1972-05-18 1976-05-12 Lilly Industries Ltd Benzoxazole derivatives
SU509046A1 (ru) 1975-02-21 1984-06-23 Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени
US4675332A (en) 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
GB8610981D0 (en) 1986-05-06 1986-06-11 Ici America Inc Quinoline amides
AU641052B2 (en) 1990-11-02 1993-09-09 Aventisub Ii Inc. 3-amidoindolyl derivatives
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6444221B1 (en) 1992-06-30 2002-09-03 Howard K. Shapiro Methods of treating chronic inflammatory diseases using carbonyl trapping agents
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US5472954A (en) 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5493027A (en) 1993-01-22 1996-02-20 Board Of Regents, The University Of Texas System Anticonvulsive agents and uses thereof
US5597823A (en) 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
US5742954A (en) 1996-11-22 1998-04-28 Softub, Inc. Electrically powered spa jet unit
ATE336485T1 (de) 1997-05-02 2006-09-15 Schering Ag Substituierte heterocyclen und deren verwendung in arzneimitteln
EP1080068A1 (en) 1998-03-12 2001-03-07 Novo Nordisk A/S Modulators of protein tyrosine phosphatases
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
WO2001041757A1 (en) 1999-12-10 2001-06-14 Senju Pharmaceutical Co., Ltd. Cyclodextrin-containing pharmaceutical composition
US6569879B2 (en) * 2000-02-18 2003-05-27 Merck & Co., Inc. Aryloxyacetic acids for diabetes and lipid disorders
FR2827599A1 (fr) 2001-07-20 2003-01-24 Neuro3D Composes derives de quinoleine et quinoxaline,preparation et utilisations
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
EP2324823A3 (en) 2003-03-14 2011-11-16 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
JP4564920B2 (ja) 2003-04-18 2010-10-20 株式会社最先端医学研究所 眼に適用する疾患治療剤
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US20040235892A1 (en) 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
EP2468729B1 (en) 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
EP2052720A3 (en) 2003-11-20 2009-05-06 Othera Holding, Inc. Use of at least one hydroxylamine compound for the treatment of eye disease
US20050197292A1 (en) 2004-01-30 2005-09-08 Glennda Smithson Compositions and methods for treating T-cell mediated pathological conditions
PL380611A1 (pl) 2004-02-17 2007-02-19 President And Fellows Of Harvard College Postępowanie z zaburzeniami oftalmologicznymi, włącznie ze zwyrodnieniem plamki
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2006002473A1 (en) 2004-07-02 2006-01-12 Adelaide Research & Innovation Pty Ltd Method of controlling damage mediated by alpha, beta-unsaturated aldehydes
WO2006049968A1 (en) 2004-10-28 2006-05-11 Merck & Co., Inc. Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US7973025B2 (en) * 2005-05-26 2011-07-05 Neuron Systems, Inc. Compositions and methods of treating retinal disease
EP2012789B1 (en) 2006-04-14 2013-09-25 Prana Biotechnology Limited Method of treatment of age-related macular degeneration (AMD)
CA2658793A1 (en) 2006-07-25 2008-02-07 Daniel Dumas Quinoline derivatives
RU2541430C2 (ru) 2007-10-05 2015-02-10 Акусела Инк. Композиции и способы лечения нейродегенеративных заболеваний
CN102177157A (zh) * 2008-08-12 2011-09-07 西特里斯药业公司 作为沉默调节蛋白调节剂的苯并*唑类、苯并噻唑类和相关的类似物
WO2010133672A1 (en) 2009-05-20 2010-11-25 Clanotech Ab Derivatives of quinoline-3-carboxylic acid and their medical use
WO2011008202A1 (en) 2009-07-15 2011-01-20 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
CA2782015C (en) * 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
DK2663550T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
EP2670439B1 (en) 2011-01-31 2019-03-13 PVAC Medical Technologies Ltd. Active principle for mitigating undesired medical conditions
KR20150118106A (ko) 2012-12-20 2015-10-21 알데이라 테라퓨틱스, 아이엔씨. 페리-카르비놀
HK1217439A1 (zh) * 2013-01-23 2017-01-13 Aldeyra Therapeutics, Inc. 与毒性醛相关的疾病和治疗

Also Published As

Publication number Publication date
IL239736A0 (en) 2015-08-31
CN105228989A (zh) 2016-01-06
EP2948436A1 (en) 2015-12-02
SG11201505599YA (en) 2015-08-28
MX2015009444A (es) 2016-04-15
AU2014209585A1 (en) 2015-07-23
US20150344447A1 (en) 2015-12-03
KR20150120380A (ko) 2015-10-27
US10111862B2 (en) 2018-10-30
US20190125729A1 (en) 2019-05-02
JP6266023B2 (ja) 2018-01-24
EP2948436A4 (en) 2016-07-13
CA2898869A1 (en) 2014-07-31
WO2014116593A1 (en) 2014-07-31
JP2016505637A (ja) 2016-02-25
RU2015126015A (ru) 2017-03-03

Similar Documents

Publication Publication Date Title
HK1217490A1 (zh) 黃斑變性治療中的新穎捕獲劑
IL256085B (en) A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
EP3157463A4 (en) Methods and devices for treating posterior ocular disorders
EP3096617A4 (en) Compositions and methods for treating ocular diseases
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
SG10201912901YA (en) Compositions and methods for treating and preventing macular degeneration
SG11201912228WA (en) Agents, uses and methods for treatment
SG11201606101WA (en) Compositions and methods for treating and preventing macular degeneration
EP3095423A4 (en) Disposable pant-type underwear, and manufacturing method therefor
WO2016007540A3 (en) Compositions and methods for treating dengue virus infection
EP3192512A4 (en) Novel pharmaceutical composition for urinary incontinence prevention and/or treatment
LT3229790T (lt) Kompozicijos, apimančios vidutinės grandinės trigliceridus, skirtos panaudoti epilepsijos gydyme
EP3240778A4 (en) Methods and agents for treating disease
EP3103446A4 (en) Pharmaceutical preparation for preventing and treating progressive myopia
GB2554624B (en) Process for the Treatment of Ashes and Digestates, Treated Ashes and Digestates thus obtained and uses thereof.
SI3157918T1 (sl) 2-aril-4-hidroksi-1,3-tiazolni derivati, uporabni kot inhibitorji TRPM8 pri zdravljenju nevralgije, bolečine, KOPB in astme
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
IL252394A0 (en) Methods for preventing, reducing or treating macular degeneration
ZA201608558B (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
EP3235808A4 (en) Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
EP3139744A4 (en) Methods and compositions for treating and preventing tinnitus
EP3183270A4 (en) Hiv antibody therapy as treatment substitute
EP3189858A4 (en) Ecological filter for conditioning and preserving corpses, human remains and cadaverous remains
PL3481194T3 (pl) Wodne kompozycje do zaprawiania nasion, zaprawione nimi nasiona i sposoby zaprawiania nasion